Global Market Study on Immune Checkpoint Inhibitors

Aug 2018| PMR547B| Persistence Market Research

Sample Report

Report Highlights

Persistence Market Research (PMR) offers an 8-year forecast on the global immune checkpoint inhibitors market. The primary objective of the report is to offer updates and information related to market opportunities in the global immune checkpoint inhibitors market.

Report Description

In terms of revenue, the global immune checkpoint inhibitors market is expected to register a CAGR of 14.6% during the forecast period, 2018–2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global immune checkpoint inhibitors market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global immune checkpoint inhibitors market are presented in the report.

The global market for immune checkpoint inhibitors is expected to witness high growth in terms of value in high economic countries due to fast FDA approvals for novel and innovative immune checkpoint inhibitors through combination therapy coupled with growing adoption of immune checkpoint inhibitors for cancer treatment. Additionally, increasing investments in the research and development sector for the approval of immune checkpoint inhibitors for other cancer applications is also expected to drive the growth of the market for immune checkpoint inhibitors.

The report includes immune checkpoint inhibitors, such as PD-1, PD-L1 and CTLA-4. The same are considered for the calculation of total revenue generated by companies by immune checkpoint inhibitors. Currency fluctuations and inflation are not considered while calculating the revenue of the immune checkpoint inhibitors market

The revenue from the immune checkpoint inhibitors market in Asia Pacific is expected to expand at the relatively higher CAGR due to growing adoption of drugs and therapies for cancer and increased approvals of immune checkpoint inhibitors in the region. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the drug class, therapeutic application, distribution channel and regions. The report provides analysis of the global immune checkpoint inhibitors market in terms of market value (US$ Mn).

The global immune checkpoint inhibitors market is segmented on the basis of drug class into:
PD-1
PD-L1
CTLA-4
The report begins with the market definition of immune checkpoint inhibitors, followed by definitions of the different drug class. The market dynamics section includes PMR’s analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global immune checkpoint inhibitors market.

The report analyzes the immune checkpoint inhibitors market on the basis of therapeutic application and distribution channel and presents forecast in terms of value for the next 8 years. On the basis of therapeutic application, the global immune checkpoint inhibitors market is segmented into:

Lung Cancer
Melanoma
Squamous Cell Carcinoma
Urothelial Carcinoma
Blood cancer
Other Cancers
On the basis of the distribution channel, the global immune checkpoint inhibitors market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Next, the report analyzes the market on the basis of regions and presents forecast in terms of value for the next 8 years. On the basis of region, the global canine arthritis treatment market is segmented into:

North America
U.S.
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
Russia
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Australia & New Zealand
ASEAN
Rest of APEJ
Japan
Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
In addition, we have considered year-on-year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global immune checkpoint inhibitors market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the canine arthritis treatment market. To understand the key segments in terms of their growth and performance in the global immune checkpoint inhibitors market, Persistence Market Research has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in immune checkpoint inhibitors market.

In the final section of the report, the ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global immune checkpoint inhibitors market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the immune checkpoint inhibitors market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global immune checkpoint inhibitors market.

Detailed profiles of immune checkpoint inhibitors drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the immune checkpoint inhibitors market are Bristol-Myers Squibb, AstraZeneca, Merck KGaA, Merck & Co, Novartis AG, Sanofi, Roche Holdings AG, Incyte Corporation, among others.

Table 1 : List of Key Immune Checkpoint Inhibitor Manufacturers
Table 2 : Number of FDA Approvals (2010-2017)
Table 3 : Bristol-Myers Squib Immune Checkpoint Inhibitors Pipeline
Table 4 : AstraZeneca Immune Checkpoint Inhibitors Pipeline
Table 5 : Roche Holdings AG Immune Checkpoint Inhibitors Pipeline
Table 6 : Merck KgaA Immune Checkpoint Inhibitors Pipeline
Table 7 : Others Immune Checkpoint Inhibitors Pipeline
Table 8 : North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 9 : North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 10 : North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 11 : North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 12 : Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 13 : Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 14 : Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 15 : Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 16 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 17 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 18 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 19 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 20 : APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 21 : APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 22 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 23 : APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 24 : Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 25 : Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 25 : Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channe6
Table 27 : MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 28 : APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 29 : MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 30 : MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 31 : Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013ï¿½2016 and Forecast 2017ï¿½2026, By Region
Table 32 : Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013ï¿½2016 and Forecast 2017ï¿½2026, By Drug Class
Table 33 : Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013ï¿½2016 and Forecast 2017ï¿½2026, By Therapeutic Applications
Table 34 : Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013ï¿½2016 and Forecast 2017ï¿½2026, By Distribution Channel

Figure 1 : Immune Checkpoint Inhibitor Market Share By Drug Class (2017)
Figure 2 : Immune Checkpoint Inhibitor Market Share By Therapeutic Application (2017)
Figure 3 : Immune Checkpoint Inhibitor Market Share By Distribution Channel (2017)
Figure 4 : Immune Checkpoint Inhibitor Market Share By Region (2017)
Figure 5 : Global Immune Checkpoint Inhibitor Market Value (US$ Mn) Forecast 2018 and 2026
Figure 6 : Global Healthcare Expenditure in US$ Tn (2013ï¿½2020)
Figure 7 : Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Figure 8 : Number of FDA approved pharmaceuticals (2010-2017)
Figure 9 : Pipeline Analysis Based on Company (2017)
Figure 10 : Pipeline Analysis Based on Phase (2017)
Figure 11 : Pipeline Analysis Based on API (2017)
Figure 12 : Pipeline Analysis Based on Target (2017)
Figure 13 : Pipeline Analysis Based on Therapeutic Area (2017)
Figure 14 : Bristol-Myers Squib Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 15 : Bristol-Myers Squib Pipeline Analysis Based on Phase (2017)
Figure 16 : Bristol-Myers Squib Pipeline Analysis Based on API (2017)
Figure 17 : Bristol-Myers Squib Pipeline Analysis Based on Target (2017)
Figure 18 : AstraZeneca Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 19 : AstraZeneca Pipeline Analysis Based on Phase (2017)
Figure 20 : AstraZeneca Pipeline Analysis Based on API (2017)
Figure 21 : AstraZeneca Pipeline Analysis Based on Target (2017)
Figure 22 : Pipeline Analysis Based on Phase (2017)
Figure 23 : Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 24 : Pipeline Analysis Based on Phase (2017)
Figure 25 : Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 26 : Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 27 : Pipeline Analysis Based on Phase (2017)
Figure 28 : Pipeline Analysis Based on API (2017)
Figure 29 : Pipeline Analysis Based on Target (2017)
Figure 30 : North America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 31 : North America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018ï¿½2026, by Country
Figure 32 : U.S. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 33 : Canada Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 34 : North America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 35 : North America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 36 : North America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 37 : North America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 38 : North America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 39 : North America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 40 : North America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 41 : North America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 42 : North America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 43 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 44 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 45 : North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 46 : North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 47 : North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 48 : North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 49 : Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 50 : Latin America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018ï¿½2026, by Country
Figure 51 : Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 52 : Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 53 : Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 54 : Latin America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 55 : Latin America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 56 : Latin America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 57 : Latin America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 58 : Latin America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 59 : Latin America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 60 : Latin America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 61 : Latin America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 62 : Latin America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 63 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 64 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 65 : Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 66 : Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 67 : Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 68 : Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 69 : Europe Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 70 : Europe Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018ï¿½2026, by Country
Figure 71 : U.K. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 72 : Germany Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 73 : Russia Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 74 : France Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 75 : Italy Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 76 : Spain Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 77 : Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 78 : Europe PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 79 : Europe PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 80 : Europe CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 81 : Europe Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 82 : Europe Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 83 : Europe Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 84 : Europe Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 85 : Europe Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 86 : Europe Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 87 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 88 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 89 : Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 90 : Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 91 : Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 92 : Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 93 : APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 94 : APEJ Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018ï¿½2026, by Country
Figure 95 : India Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 96 : China Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 97 : Australia & New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 98 : ASEAN Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 99 : Rest of APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 100 : APEJ PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 101 : APEJ PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 102 : APEJ CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 103 : APEJ Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 104 : APEJ Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 105 : APEJ Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 106 : APEJ Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 107 : APEJ Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 108 : APEJ Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 109 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 110 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 111 : APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 112 : APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 113 : APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 114 : APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 115 : Japan Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 116 : Japan PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 117 : Japan PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 118 : Japan CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 119 : Japan Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 120 : Japan Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 121 : Japan Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 122 : Japan Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 123 : Japan Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 124 : Japan Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 125 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 126 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 127 : Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 128 : Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 129 : Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 130 : MEA Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018ï¿½2026
Figure 131 : MEA Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018ï¿½2026, by Country
Figure 132 : GCC Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 133 : South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 134 : Rest of MEA Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 135 : MEA PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 136 : MEA PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 137 : MEA CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 138 : MEA Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 139 : MEA Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 140 : MEA Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 141 : MEA Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 142 : MEA Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 143 : MEA Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 144 : Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 145 : Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018ï¿½2026
Figure 146 : MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 147 : MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 148 : MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 149 : MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 150 : Key Developments, By type of Development
Figure 151 : Key Developments, By Year
Figure 152 : Key Developments, By Company
Figure 153 : Key Development Snapshot, by Type of Development
Figure 154 : Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Region, 2018 & 2026
Figure 155 : Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Region, 2018ï¿½2026
Figure 156 : Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Region, 2018ï¿½2026
Figure 157 : Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Drug Class, 2018 & 2026
Figure 158 : Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Drug Class, 2018ï¿½2026
Figure 159 : Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Drug Class, 2018ï¿½2026
Figure 160 : Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Therapeutic Application, 2018 & 2026
Figure 161 : Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Therapeutic Application, 2018ï¿½2026
Figure 162 : Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Therapeutic Application, 2018ï¿½2026
Figure 163 : Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Distribution Channel, 2018 & 2026
Figure 164 : Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Distribution Channel, 2018ï¿½2026
Figure 165 : Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Distribution Channel, 2018ï¿½2026
Figure 166 : Global Immune Checkpoint Inhibitors Market Value Analysis and Forecast, 2016ï¿½2025 (US$ Mn)
Figure 167 : Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2013ï¿½2017
Figure 168 : Global Immune Checkpoint Inhibitors Market Absolute $ Opportunity (US$ Mn), 2017ï¿½2026

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Similar Reports from Persistence Market Research